Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:39 2022-11-29 am EST
88.19 EUR   +0.34%
10:31aUK regulator calls for review of reactions in eyes to Sanofi asthma drug
RE
09:55aUK regulator says reactions in eye from Sanofi drug must be quickly reviewed
RE
11/28DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Xenpozyme for Treatment of Niemann-Pick Disease
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

SANOFI : Deutsche Bank sticks Neutral

09/21/2022 | 07:14am EST

In a research note published by Emmanuel Papadakis, Deutsche Bank gives a Neutral rating to the stock. The target price remains unchanged at EUR 85.


ę MarketScreener with dpa-AFX Analyser 2022
All news about SANOFI
10:31aUK regulator calls for review of reactions in eyes to Sanofi asthma drug
RE
09:55aUK regulator says reactions in eye from Sanofi drug must be quickly reviewed
RE
11/28DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Xenpozyme for Treatme..
MT
11/28Drugmaker Sanofi Relocates to New Paris Headquarters
MT
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amg..
AQ
11/21Sanofi Receives Marketing Authorization for Enjaymo from the European Commission
CI
11/21SANOFI : UBS remains Neutral
MD
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Provention Bio, Inc. - TZIELD approved by FDA as the first and only treatment indicated..
AQ
11/18Provention Bio diabetes drug to cost $13,850/vial
RE
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 44 154 M 45 850 M 45 850 M
Net income 2022 7 749 M 8 047 M 8 047 M
Net Debt 2022 6 741 M 7 000 M 7 000 M
P/E ratio 2022 14,6x
Yield 2022 4,08%
Capitalization 110 B 114 B 114 B
EV / Sales 2022 2,65x
EV / Sales 2023 2,46x
Nbr of Employees 95 442
Free-Float 87,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 87,89 €
Average target price 107,92 €
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-0.78%114 454
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
MERCK & CO., INC.41.51%274 964